These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 28179449)

  • 1. The GIP/GIPR axis is functionally linked to GH-secretion increase in a significant proportion of
    Regazzo D; Losa M; Albiger NM; Terreni MR; Vazza G; Ceccato F; Emanuelli E; Denaro L; Scaroni C; Occhi G
    Eur J Endocrinol; 2017 May; 176(5):543-553. PubMed ID: 28179449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The glucose-dependent insulinotropic polypeptide receptor is overexpressed amongst GNAS1 mutation-negative somatotropinomas and drives growth hormone (GH)-promoter activity in GH3 cells.
    Occhi G; Losa M; Albiger N; Trivellin G; Regazzo D; Scanarini M; Monteserin-Garcia JL; Fröhlich B; Ferasin S; Terreni MR; Fassina A; Vitiello L; Stalla G; Mantero F; Scaroni C
    J Neuroendocrinol; 2011 Jul; 23(7):641-9. PubMed ID: 21554434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypermethylator Phenotype and Ectopic GIP Receptor in GNAS Mutation-Negative Somatotropinomas.
    Hage M; Chaligné R; Viengchareun S; Villa C; Salenave S; Bouligand J; Letouzé E; Tosca L; Rouquette A; Tachdjian G; Parker F; Lombès M; Lacroix A; Gaillard S; Chanson P; Kamenický P
    J Clin Endocrinol Metab; 2019 May; 104(5):1777-1787. PubMed ID: 30376114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pathogenic role of the GIP/GIPR axis in human endocrine tumors: emerging clinical mechanisms beyond diabetes.
    Regazzo D; Barbot M; Scaroni C; Albiger N; Occhi G
    Rev Endocr Metab Disord; 2020 Mar; 21(1):165-183. PubMed ID: 31933128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KDM1A genotyping and expression in 146 sporadic somatotroph pituitary adenomas.
    Chasseloup F; Regazzo D; Tosca L; Proust A; Kuhn E; Hage M; Jublanc C; Mokhtari K; Dalle Nogare M; Avallone S; Ceccato F; Tachdjian G; Salenave S; Young J; Gaillard S; Parker F; Boch AL; Chanson P; Bouligand J; Occhi G; Kamenický P
    Eur J Endocrinol; 2024 Feb; 190(2):173-181. PubMed ID: 38330165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GIP receptor antagonism eliminates paradoxical growth hormone secretion in some patients with acromegaly.
    Jensen MH; Gasbjerg LS; Skov-Jeppesen K; Jacobsen JCB; Poulsen SS; Zhou C; Jakubauskaite R; Poulsen FR; Bonde C; Albarazi M; Halle B; Christiansen CB; Sanni SJ; Byberg S; Hoe B; Holst JJ; Dela F; Rasmussen AK; Knop FK; Arlien-Søborg MC; Melmed S; Jørgensen JOL; Andersen MS; Hartmann B; Klose MC; Feldt-Rasmussen U; Sparre-Ulrich AH; Rosenkilde MM
    J Clin Endocrinol Metab; 2024 Aug; ():. PubMed ID: 39172542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disruption of GIP/GIPR axis in human adipose tissue is linked to obesity and insulin resistance.
    Ceperuelo-Mallafré V; Duran X; Pachón G; Roche K; Garrido-Sánchez L; Vilarrasa N; Tinahones FJ; Vicente V; Pujol J; Vendrell J; Fernández-Veledo S
    J Clin Endocrinol Metab; 2014 May; 99(5):E908-19. PubMed ID: 24512489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucose-dependent insulinotropic polypeptide induced growth hormone secretion in acromegaly.
    Umahara M; Okada S; Ohshima K; Mori M
    Endocr J; 2003 Oct; 50(5):643-50. PubMed ID: 14614222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucose-dependent insulinotropic polypeptide (GIP) and its receptor (GIPR): cellular localization, lesion-affected expression, and impaired regenerative axonal growth.
    Buhren BA; Gasis M; Thorens B; Müller HW; Bosse F
    J Neurosci Res; 2009 Jun; 87(8):1858-70. PubMed ID: 19170165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MANAGEMENT OF ENDOCRINE DISEASE: Etiology and outcome of acromegaly in patients with a paradoxical GH response to glucose.
    Hage M; Janot C; Salenave S; Chanson P; Kamenický P
    Eur J Endocrinol; 2021 May; 184(6):R261-R268. PubMed ID: 33830942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional expression of glucose-dependent insulinotropic polypeptide receptors is coupled to differentiation in a human adipocyte model.
    Weaver RE; Donnelly D; Wabitsch M; Grant PJ; Balmforth AJ
    Int J Obes (Lond); 2008 Nov; 32(11):1705-11. PubMed ID: 18779825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel GIP receptor splice variant influences GIP sensitivity of pancreatic beta-cells in obese mice.
    Harada N; Yamada Y; Tsukiyama K; Yamada C; Nakamura Y; Mukai E; Hamasaki A; Liu X; Toyoda K; Seino Y; Inagaki N
    Am J Physiol Endocrinol Metab; 2008 Jan; 294(1):E61-8. PubMed ID: 17971513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Methylation Analysis of the
    Dalle Nogare M; D'Annunzio S; Vazza G; Regazzo D; Picello L; Denaro L; Voltan G; Scaroni C; Ceccato F; Occhi G
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Marked cortisol production by intracrine ACTH in GIP-treated cultured adrenal cells in which the GIP receptor was exogenously introduced.
    Fujii H; Tamamori-Adachi M; Uchida K; Susa T; Nakakura T; Hagiwara H; Iizuka M; Okinaga H; Tanaka Y; Okazaki T
    PLoS One; 2014; 9(10):e110543. PubMed ID: 25334044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetically Predicted Glucose-Dependent Insulinotropic Polypeptide (GIP) Levels and Cardiovascular Disease Risk Are Driven by Distinct Causal Variants in the
    Bowker N; Hansford R; Burgess S; Foley CN; Auyeung VPW; Erzurumluoglu AM; Stewart ID; Wheeler E; Pietzner M; Gribble F; Reimann F; Bhatnagar P; Coghlan MP; Wareham NJ; Langenberg C
    Diabetes; 2021 Nov; 70(11):2706-2719. PubMed ID: 34426508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly.
    Neto LV; Machado Ede O; Luque RM; Taboada GF; Marcondes JB; Chimelli LM; Quintella LP; Niemeyer P; de Carvalho DP; Kineman RD; Gadelha MR
    J Clin Endocrinol Metab; 2009 Jun; 94(6):1931-7. PubMed ID: 19293270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Percent reduction of growth hormone levels correlates closely with percent resected tumor volume in acromegaly.
    Schwyzer L; Starke RM; Jane JA; Oldfield EH
    J Neurosurg; 2015 Apr; 122(4):798-802. PubMed ID: 25423276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents.
    Gasbjerg LS; Gabe MBN; Hartmann B; Christensen MB; Knop FK; Holst JJ; Rosenkilde MM
    Peptides; 2018 Feb; 100():173-181. PubMed ID: 29412817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GIP-GIPR promotes neurite outgrowth of cortical neurons in Akt dependent manner.
    Teng L; Guan T; Guo B; Ma C; Lin G; Wu R; Xu M; Liu M; Liu Y
    Biochem Biophys Res Commun; 2021 Jan; 534():121-127. PubMed ID: 33321289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of pituitary tumour-derived, N-terminally truncated isoform of fibroblast growth factor receptor 4 (ptd-FGFR4) correlates with tumour invasiveness but not with G-protein alpha subunit (gsp) mutation in human GH-secreting pituitary adenomas.
    Morita K; Takano K; Yasufuku-Takano J; Yamada S; Teramoto A; Takei M; Osamura RY; Sano T; Fujita T
    Clin Endocrinol (Oxf); 2008 Mar; 68(3):435-41. PubMed ID: 18070145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.